Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
Cervical Cancer, Vaginal Cancer
About this trial
This is an interventional treatment trial for Cervical Cancer focused on measuring stage III cervical cancer, recurrent cervical cancer, stage IVB cervical cancer, stage IVA cervical cancer, stage III vaginal cancer, stage IVA vaginal cancer, stage IVB vaginal cancer, recurrent vaginal cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed recurrent metastatic or locally advanced cervical or vaginal carcinoma that is not curable with surgery or radiotherapy Tumor is human papillomavirus positive by polymerase chain reaction Bidimensionally measurable disease by clinical examination or radiographic imaging Availability of an genotypically HLA-identical sibling donor (excluding identical twins) No brain metastases PATIENT CHARACTERISTICS: Age: Under 65 Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT and SGPT no greater than 2 times ULN Renal: Creatinine clearance at least 40 mL/min Cardiovascular: Cardiac ejection fraction at least 40% No history of congestive heart failure No poorly controlled hypertension Pulmonary: No severe defects in pulmonary function No supplementary continuous oxygen Other: Not pregnant or nursing Fertile patients must use effective contraception during and for 12 months after study completion HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: Concurrent growth factors for severe persistent or febrile neutropenia after transplantation allowed Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics
Sites / Locations
- Fred Hutchinson Cancer Research Center